/ Not yet recruiting早期临床1期IIT A Single-Arm, Open-Label, Exploratory Clinical Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy of a Novel SPECT Tracer 177Lu-AF03 in Patients With Malignant Solid Tumors
This study evaluates 177Lu-AF03, a bispecific heterodimeric peptide targeting both FAP and integrin αvβ6, for safety, biodistribution, radiation dosimetry, and preliminary diagnostic efficacy in patients with malignant solid tumors. Preclinical studies showed enhanced tumor uptake, prolonged retention, and low uptake in non-target organs. Eight patients with confirmed malignant solid tumors will receive a single intravenous injection of 177Lu-AF03, followed by SPECT/CT imaging at multiple time points. Safety will be monitored until Day 7 post-injection.
100 项与 177Lu-AF03 相关的临床结果
100 项与 177Lu-AF03 相关的转化医学
100 项与 177Lu-AF03 相关的专利(医药)
100 项与 177Lu-AF03 相关的药物交易